Last Name
|
First Name
|
Country
|
Title
|
| Ashe |
Karen |
USA |
Tau Cleavage by Caspase-2 in Tauopathies |
| Attems |
Johannes |
UK |
The Overlap Between Alzheimer and Lewy Body Pathologies |
| Barthélemy |
Nicolas |
USA |
Tau Isoforms Changes in Brain and Biofluids: Diagnostic Perspective and New Insights on Pathways Involved in AD Tauopathy |
| Bateman |
Randall |
USA |
Advances in Alzheimer’s Disease Prevention Trials: DIAN-TU Updates and Transition to Blood Test Screening |
| Bezard |
Erwan |
France |
Astonishing Impact of Patient-Derived a-Synuclein Extracts and Stealth Recombinant a-Synuclein Polymorphs Calls for Careful Thinking Before Developing Therapeutics |
| Bezprozvanny |
Ilya |
USA |
Sigma 1 Receptor as Potential Therapeutic Target for AD |
| Blennow |
Kaj |
Sweden |
Blood Biomarkers for Alzheimer’s Disease – the Promise for Screening, Diagnostics and Therapy Monitoring |
| Blurton Jones |
Mathew |
USA |
Examining the Function of AD Risk Genes in Human Microglia and Chimeric Models |
| Brooks |
David |
UK |
Does Inflammation Protect or Exacerbate AD and PD Progression |
| Buee |
Luc |
France |
Anti-Tau Immunotherapy: Side Effects and Specificity |
| Canavan |
Michelle |
Ireland |
Association of Blood Pressure Lowering with Incident Dementia or Cognitive Impairment |
| Checler |
Frédéric |
France |
XBP1S-PINK1 Functional Interplay Unravels Molecular Links Between Reticular Stress and Mitophagy |
| Chiba-Falek |
Ornit |
USA |
Decoding the Genetic Architecture of Late-Onset Alzheimer’s Disease Using Single-Cell Multi-Omics |
| Cleveland |
Don |
USA |
“Identity Theft”: Therapeutic Generation of Replacement Neurons by Identity Conversion From Astrocytes in Parkinson’s and Alzheimer’s Disease Models |
| Cuello |
Claudio A. |
Canada |
Arguments for an Early Alzheimer’s Nano-Lithium Therapy |
| Cummings |
Jeffrey |
USA |
Alzheimer Therapeutics: Potential Pipeline Predictions |
| De Strooper |
Bart |
Belgium |
HUMAN MICROGLIA IN AD |
| Diamond |
Marc |
USA |
Functional Classification of Tau Prions and Their Relationship to Tauopathies |
|
|
|
|
|
|
|
|
| Fändrich |
Marcus |
Germany |
Cryo-EM Structure and Polymorphism of Abeta Amyloid Fibrils Purified From Alzheimer’s Brain Tissue |
| Ferretti |
Maria Teresa |
Switzerland |
Sex and Gender Differences – Towards Precision Medicine for Brain Disorders |
| Frenkel |
Dan |
Israel |
Presenilin 1 Role in Mediating Glia Cell Activity in Alzheimer’s Disease |
| Galvin |
James |
USA |
Designing Dementia Prevention Studies: Using Proxy Biomarkers to Identify At-Risk Individuals |
| Gerwert |
Klaus |
Germany |
Aβ-Structure as Precise Plasma Biomarker for Symptom-Free Alzheimer’s Disease Stage |
| Giladi |
Nir |
Israel |
LRRK2-PD Vs. GBA-PD, An Evolving Story of Genetic Role in Parkinson’s Disease |
| Goate |
Alison |
USA |
Genetic Studies Implicate Microglial Function in Alzheimer’s Disease Risk |
| Gold |
Gabriel |
Switzerland |
Making Sense of Mixed Pathology in the Oldest-Old |
| Golde |
Todd |
USA |
Non-Amyloid Plaque Associated Proteins as Key Mediators of Alzheimer’s Pathology |
| Growdon |
John |
USA |
PET Scans Aid in the Differential Diagnosis of Parkinsonian Syndromes |
| Haass |
Christian |
Germany |
Therapeutic Modulation of TREM2 function |
| Halliday |
Glenda |
Australia |
The Role of Glia in Progressing Alpha-Synuclein Pathologies |
| Hansson |
Oskar |
Sweden |
NOVEL FLUID BIOMARKERS FOR ALZHEIMER’S DISEASE |
|
|
|
|
| Heneka |
Michael |
Germany |
Mutual Interactions Between Immunity and Degeneration in Alzheimer’s Disease |
| Herz |
Joachim |
USA |
A Rational Preventive Approach to Reverse ApoE4 AD Risk |
| Higuchi |
Makato |
Japan |
Multimodal Imaging of Tau and Alpha-Synuclein Pathologies |
| Holtzman |
David |
USA |
Role of Astrocyte-Derived ApoE in Tau-Mediated Neurodegeneration |
| Hyman |
Bradley |
USA |
Complexity of Dissecting Dementia Progression in AD |
| Iaedecola |
Costantino |
USA |
Neurovascular Bases of Neurodegeneration |
| Isacson |
Ole |
USA |
Neurons, Astrocytes and Microglia Uniquely Change Their Lipid Load With a Primary Pathology in Glycolipid and Metabolic Pathways in Parkinson’s Disease |
| Iwatsubo |
Takeshi |
Japan |
Preclinical Alzheimer’s Clinical Trials: TRC-PAD and A4 in Japan |
| Jack |
Clifford |
USA |
The Future of Imaging and Biofluid Alzheimer’s Biomarkers |
| Jeon |
Beomseok |
Korea |
GI Synucleinothay as a Biomarker in Parkinson’s Disease: An Update |
| Krainc |
Dimitri |
USA |
Mechanistic Insights Into Familial and Sporadic Parkinson’s Disease: Therapeutic Implications |
| Kulisevsky |
Jaime |
Spain |
Cognitive Aspects of Huntington’s Disease |
| Laferla |
Frank |
USA |
MODEL-AD 2021 Overview: Developing the Next Generation of AD Mouse Models |
| Lazarov |
Orly |
USA |
Molecular and Cellular Mechanisms Underlying Memory Failure in Alzheimer’s Disease |
| Lee |
Virginia |
USA |
Tau Strains Determine Disease-Specific Cell Type Vulnerability |
| Lee |
Seung-Jae |
Korea |
Interplay Between Synucleinopathy Propagation and Neuroinflammation |
| Lemere |
Cynthia |
USA |
Novel Global and Cell-Specific Complement C3 Conditional Knockout Mouse Models |
| Lipton |
Stuart |
USA |
Hidden Networks of Transnitrosylated Proteins Underlie Synaptic Damage in Neurodegenerative Diseases. |
|
|
|
|
| Mandelkow |
Eckhard |
Germany |
Tau Phosphorylation vs. Aggregation vs. Toxicity |
| Marek |
Ken |
USA |
Novel Biomarkers Across the PD Continuum – PPMI 2.0 |
| Masliah |
Eliezer |
USA |
Progress Towards Understanding Alzheimer’s Disease and Related Dementias in the Context of Aging |
|
|
|
|
| McLean |
Pamela |
USA |
Therapeutic Strategies to Target Alpha-Synuclein Levels in Synucleinopathies |
| Michaelson |
Daniel M. |
Israel |
ApoE4: An Emerging Therapeutic Target of Alzheimer’s Disease |
| Morgan |
Dave |
USA |
Comparison of Different Methods of Inducing Tau Pathology in Mice. Transgenesis, Intracranial Transduction and Systemic Tranduction |
| Morizane |
Asuka |
Japan |
Cell Therapy for Parkinson’s Disease With Induced Pluripotent Stem Cells |
| Morris |
John |
USA |
Racial Differences in Molecular Biomarkers for Alzheimer Disease |
| Mucke |
Lennart |
USA |
Molecular and Cellular Modulators of Neural Network Dysfunction in Alzheimer’s Disease: From Tau to Microglia |
| Multhaup |
Gerhard |
Canada |
Metabolism of BACE1-Mediated Amyloid Clearance Products |
| Nielsen |
Henrietta |
Sweden |
The Significance of Apolipoprotein E Levels in Relation to Neurodegenerative Disease in Humans |
| Nordberg |
Agneta |
Sweden |
Multimodal Translational Imaging: Association of Amyloid, Tau, Astrogliosis and Synapse Loss in AD and Non-AD Dementia. |
| Okazawa |
Hitoshi |
Japan |
Deciphering and Tacking the Ultra-Early Phase Pathology of Alzheimer’s Disease |
| Outerio |
Tiago |
Germany |
Glycation: An Age-Associated Process That Drives Neurodegeneration in Synucleinopathies |
| Petersen |
Ronald |
USA |
Alzheimer’s Diagnosis in the Era of Biomarkers 2021 |
| Poewe |
Werner |
Austria |
DMT in PD – Where Do We Stand? |
| Polymenidou |
Magdalini |
Switzerland |
Aggregation-Dependent and Independent Mechanisms of Toxicity in TDP-43 and FUS Proteinopathies |
| Prado |
Marco |
Canada |
Cell Type-Specific Cholinergic Signalling Improves Plaque Pathology and Neuroinflammation in Humanized Knock-in APP Mice |
| Price |
Julie |
USA |
PET Methodology Considerations for Amyloid and Tau Imaging |
| Quiroz |
Yakeel |
USA |
Age-Related Trajectory of Tau Pathology in Preclinical Autosomal Dominant Alzheimer’s Disease |
| Rabinovici |
Gil |
USA |
Impact of Amyloid PET on Health Outcomes: Update on the IDEAS study |
| Ranum |
Laura |
USA |
Ran Translation in C9ORF72 ALS/FTD and Other Repeat Expansion Diseases: Molecular Insights and Therapeutic Opportunities |
| Rektorova |
Irena |
Czech Republic |
Cognitive Impairment in Parkinson’s Disease: Neural Correlates and Treatment Approaches |
| Rosa-Neto |
Pedro |
Canada |
Staging Alzheimer’s Disease Using Biomarkers: Application for Clinical Trials |
| Sabbagh |
Marwan |
USA |
Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease |
| Salloway |
Stephen |
USA |
Creating Pathways for Breakthroughs in Alzheimer’s Disease |
| Schapira |
Antony |
UK |
Novel Therapies for GBA-Parkinson Disease |
| van der Flier |
Wiesje |
The Netherlands |
The ATN Framework for AD Research Set to Work: Real World Evidence |
| Schlossmacher |
Michael |
Canada |
A Redox Function for Parkin Explains Its Selective Neuroprotection in Adult Human Brain |
| Schmidt |
Reinhold |
Austria |
MRI as a Tool to Study Microstructural Changes in Aging and Dementia |
| Schmitz |
Taylor |
Canada |
In Vivo Molecular Imaging of Cortical Cholinergic Denervation in Preclinical Alzheimer’s Disease |
| Schneider |
Julie |
USA |
Neuropathologic Insights Into Mechanisms of Disease in Alzheimer’s and Other Dementias |
| Segal |
Menahem |
Israel |
POSSIBLE INVOLVEMENT OF MITOCHONDRIA, CALCIUM STORES AND PRESENILIN IN AD |
| Shen |
Jie |
USA |
APP and Presenilin in the Brain |
| Sisodia |
Sam |
USA |
Influence of the Gut Microbiome on Aβ Amyloidosis and Neuroinflammation |
| Snyder |
Peter |
USA |
Retinal Biomarkers for Pre-Clinical Alzheimer’s Disease: What We Know, What We Don’t Know, and How to Move Forward |
| Soreq |
Hermona |
Israel |
Investigating Alzheimer’s Disease-Related Roles of Transfer RNA Fragments in Human Brain Nuclei |
| Spillantini |
Maria Grazia |
UK |
Investigating Alpha-Synuclein Spreading From Gut to Brain |
| St. George-Hyslop |
Peter |
Canada |
Downstream TREM2 Signalling in Microglia |
| Stocchi |
Fabrizio |
Italy |
Active and Passive Immunization in the Treatment of Parkinson’s Disease |
| Suh |
Yoo Hun |
Korea |
Effects of DHED and its Derivatives, Multitarget Candidates, for the Treatment of AD |
| Thal |
Dietmar |
Belgium |
Neuropathological Classification Strategies in Alzheimer’s Disease and Its Impact on Clinical Practice and Basic Research. |
| Thinakaran |
Gopal |
USA |
The functional role of the GWAS risk factor BIN1 in neurons and microglia |
| Trojanowski |
John Q. |
USA |
Copathologies in AD and PD |
| Van Broeckhoven |
Christine |
Belgium |
Rare Compound Coding Variants Might Increase Risk in Sporadic Patients With Neurodegenerative Brain Diseases |
| Vassar |
Robert |
USA |
The Role of Angiotensin Converting Enzyme in Alzheimer’s Disease |
| Verma |
Anjay |
USA |
Molecular Imaging of CNS Intrathecal Pharmacology |
| Villemagne |
Victor |
Australia |
Amyloid, TAU and reactive astrocytosis in aging and Alzheimer’s disease |
| Weiner |
Michael |
USA |
Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Plasma Samples Are Available Upon Request |
| Weiner |
Howard |
USA |
Immune Mechanisms in Alzheimer’s Disease and the Role of the Microbiome |
| Wellington |
Cheryl |
Canada |
The Role of High Density Lipoproteins in the Vascular Contributions to Alzheimer’s Disease |
| Wilcock |
Donna |
USA |
Angiogenic Dysregulation in Vascular Cognitive Impairment and Dementia |
| Wilson |
Edward |
United States |
TREM1 as a Therapeutic Target for Alzheimer’s Disease |
| Wong |
Philip |
USA |
Identification of TDP-43 Cryptic Exons as Functional Fluid Biomarkers for Alzheimer’s Disease and Related Dementia |
| Wszolek |
Zbigniew |
USA |
The Biomarker Search For SCA3 |
| Wyss-Coray |
Tony |
USA |
Circulatory Factors as Regulators of Brain Aging and Neurodegeneration |
| Xu |
Huaxi |
USA |
Roles for microglial Alzheimer’s risk genes in regulation of beta-amyloid metabolism and microglia function. |
| Zetterberg |
Henrik |
Sweden |
Blood Biomarkers for Alzheimer’s Disease and Other Neurodegenerative Diseases – Utility in Clinical Trials and Practice |
| Zheng |
Hui |
USA |
TFEB-Mediated Lysosomal Regulation and Signaling in Alzheimer’s Disease |
| Zhou |
Jiawei |
China |
Ebf1 Signaling in Astrocytes Drives CNS Inflammation |
| Zlokovic |
Berislav |
USA |
Blood-Brain Barrier Dysfunction and Cognitive Decline in ApoE4 Carriers |
| Bondi |
Mark |
USA |
Objective Subtle Cognitive Difficulties Predict Amyloid Accumulation and Neurodegeneration |
| Goedert |
Michel |
UK |
Structures of Amyloid Filaments From Human Brain |
| Livesey |
Frederick |
UK |
Insights Into Pathogenesis of Alzheimer’s Disease From Human Stem Cell Systems |
| Murray |
Melissa |
USA |
Selective Vulnerability of the Cholinergic Hub in the Context of Aging and Alzheimer Disease Subtypes |
